Bolero 1 trial

Everolimus for women with trastuzumab-resistant, HER2-positive. Novartis pivotal Phase III trial shows Afinitor® significantly delays. Bolero-2 Trial for Advanced Metastatic Breast Cancer Therapy.

Everolimus in Combination With Trastuzumab and Paclitaxel in the. Everolimus: Avalanche of mTOR Data in ER+ Breast Cancer.

Apr 14, 2014 1. Lancet Oncol. 2014 May.15(6):580-91. doi: Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Andre F. Apr 2, 2009 Positive Locally Advanced or Metastatic Breast Cancer (BOLERO-1) DoubleBlind, Placebo-Controlled Multicenter Trial of Everolimus in. Jan 8, 2013 Drs. Fabrice Andre and Kathy Miller discuss the BOLERO trials and how [1] We first heard about the BOLERO trial results almost a year ago.

Treatment of HER2-positive Disease in 2013 A - The ASCO Post

Jun 2, 2013 The BOLERO-3 (Breast cancer trials of OraL EveROlimus-3) findings survival, the key secondary endpoint of the trial, are not yet mature[1]. Read the information about the Bolero-2 trial and how it challenges BOLERO-2 Successfully Challenges Conventional Sequencing of Endocrine Therapy1.

BOLERO 3: Everolimus may overcome trastuzumab resistance in

Novartis pivotal Phase III trial shows Afinitor® significantly delays. Bolero-2 Trial for Advanced Metastatic Breast Cancer Therapy. Read the information about the Bolero-2 trial and how it challenges BOLERO-2 Successfully Challenges Conventional Sequencing of Endocrine Therapy1.

Everolimus: Avalanche of mTOR Data in ER+ Breast Cancer. Everolimus for women with trastuzumab-resistant, HER2-positive.

Everolimus in Combination With Trastuzumab and Paclitaxel in the.

Apr 14, 2014 1. Lancet Oncol. 2014 May.15(6):580-91. doi: Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Andre F. Jun 2, 2013 The BOLERO-3 (Breast cancer trials of OraL EveROlimus-3) findings survival, the key secondary endpoint of the trial, are not yet mature[1]. Apr 2, 2009 Positive Locally Advanced or Metastatic Breast Cancer (BOLERO-1) DoubleBlind, Placebo-Controlled Multicenter Trial of Everolimus in.